51 results
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
17 Jan 24
Current report (foreign)
4:30pm
the numerous risks, costs and uncertainties associated with research, development and commercialization of Gracell’s pipeline programs and candidates … to research and development and track record of successfully commercializing drug candidates, and the risks associated with any such agreements or partnerships
6-K
EX-2.1
GRCL
Gracell Biotechnologies Inc
26 Dec 23
Voting and Support Agreement
8:12am
educational institution, on the other hand, in each case, that provides (A) for research and development activities involving the creation of any … of the Company and to the extent relating to the research, development or manufacture of any Company Product, each Collaboration Partner is, in compliance
6-K
EX-99.4
GRCL
Gracell Biotechnologies Inc
26 Dec 23
Voting and Support Agreement
8:12am
exchange competitive or sensitive information, integrate research and development efforts, or share external messages that state the organizations
6-K
EX-99.1
GRCL
Gracell Biotechnologies Inc
14 Nov 23
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
6:04am
for the corresponding prior year period.
Research and Development Expenses
Research and development expenses for the three months ended September 30, 2023 … to the decreased spending on research, development and clinical trials.
Administrative Expenses
Administrative expenses for the three months ended September
F-3/A
GRCL
Gracell Biotechnologies Inc
12 Sep 23
Shelf registration (foreign) (amended)
4:12pm
funds and any future earnings to fund the research and development of our product candidates and the development and growth of our business. As a result … and commercialization of our drugs.
Currently, a material portion of our research and development operations and manufacturing facilities are in China
F-3
u88urig472h2opz51l
24 Aug 23
Shelf registration (foreign)
4:03pm
6-K
EX-99.2
jw5rn4b3ldsxu8gf4n
14 Aug 23
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:52pm
6-K
EX-99.1
ltkaroj 1spfp
14 Aug 23
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:52pm
6-K
oc69fua1
7 Aug 23
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
8:07am
6-K
EX-99.1
qnt2igf
7 Aug 23
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
8:07am
6-K
EX-99.1
7b673j69etvny
16 May 23
Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update
6:08am
UPLOAD
24h 31ccs8w
27 Dec 22
Letter from SEC
12:00am
6-K
EX-99.1
kg8x0f 23aedj2c
16 Nov 22
Current report (foreign)
6:03am
6-K
EX-99.1
2pl5x
16 Nov 22
Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results
6:01am
6-K
EX-99.1
hqkd4trc0640j
15 Aug 22
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:11pm
6-K
EX-99.2
h7n62hn
15 Aug 22
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:11pm
6-K
EX-99.1
hvot5hxb jnkll1qwqv
15 Aug 22
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
8:16am
F-3/A
b5aw4 u7nwwdmis
17 Jun 22
Shelf registration (foreign) (amended)
9:10am